23:06 , Jun 7, 2018 |  BC Extra  |  Company News

Management tracks: Alder, BIO

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) hired Robert Azelby as president and CEO, effective June 13. Azelby was EVP and chief commercial officer at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired. The Biotechnology Innovation...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
17:51 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Cytori's Habeo Cell Therapy misses in Phase III scleroderma trial

Cytori Therapeutics Inc. (NASDAQ:CYTX) reported top-line data from the Phase III STAR trial in 88 patients with hand dysfunction due to scleroderma showing that Habeo Cell Therapy (ECCS-50) missed the primary endpoint of improving mean...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
23:13 , Apr 13, 2017 |  BC Week In Review  |  Financial News

Cytori completes follow-on

Cell therapy company Cytori Therapeutics Inc. (NASDAQ:CYTX) raised $9.5 million through the sale of 8.6 million shares at $1.10 in a follow-on underwritten by Maxim Group on April 11. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego,...
20:28 , Feb 3, 2017 |  BC Week In Review  |  Company News

Azaya, Cytori deal

Cytori said it will acquire Azaya’s liposomal nanoparticle technology platform, including two cancer drugs: ATI-0918, a generic nanoparticle liposomal formulation of doxorubicin; and ATI-1123 , a liposomal encapsulated docetaxel , which has completed Phase I...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
21:58 , Dec 30, 2016 |  BC Week In Review  |  Financial News

Cytori financial update

Cytori entered into a 30-month stock purchase agreement with Lincoln Park Capital Fund for up to $20 million. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego, Calif. ...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

ECCS-50: Completed Phase II enrollment

Bimini’s Kerastem Technologies LLC company completed enrollment of 70 patients in the double-blind, sham-controlled, U.S. Phase II STYLE trial evaluating 500,000 and 1 million/cm 2 subcutaneous ADRCs. Cytori granted Bimini exclusive, worldwide rights to the...